Show Summary Details
Page of

Single brain metastasis from breast cancer 

Single brain metastasis from breast cancer
Chapter:
Single brain metastasis from breast cancer
Author(s):

Thankamma Ajithkumar

DOI:
10.1093/med/9780199664535.003.0006
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 20 August 2019

Approximately 10% of patients with breast cancer present with metastatic brain disease. The majority of these patients have multiple brain metastases (78%) and solitary metastasis occurs in 14% of patients and 8% have leptomeningeal disease. While whole brain radiotherapy remains the standard of care in multiple brain metastases, surgery is usually the initial treatment for solitary brain metastasis. However, there is no consensus on the optimal postoperative management of resected solitary metastasis. Although a number of studies report clinical benefits of loco-regional treatment in metastatic breast cancer, there is a lack of consensus on its exact role. There is no standard optimal systemic treatment for metastatic breast cancer and the choice of systemic treatment depends on various patient-related factors such as menopausal status, performance etc, and disease related factors such as HER-2 and hormonal receptor status, tumour burden etc.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.